Insys Therapeutics was an Arizona company whose sublingual fentanyl spray for breakthrough cancer pain went through phase 3 trials; its marketing practices later led to criminal convictions and bankruptcy.
Insys Therapeutics, founded in 1990 and based in Chandler, Arizona, developed Subsys, a fentanyl sublingual spray approved for breakthrough pain in opioid-tolerant cancer patients, and a dronabinol oral solution. Its executives were convicted in 2019 over kickbacks to prescribers, and the company filed for bankruptcy the same year. Its phase 3 trials in cancer pain remain on ClinicalTrials.gov under Insys as lead sponsor. ClinicalTrials.gov also lists under Insys the earlier NeoPharm programmes it absorbed, including the interleukin-13 conjugated toxin IL13-PE38QQR (cintredekin besudotox) in malignant glioma (NCT00076986) and liposomal paclitaxel and docetaxel formulations.
Dronabinol is synthetic THC in a capsule, approved in 1985 for chemotherapy nausea and vomiting that other antiemetics have failed to control, and later for appetite loss in AIDS; it sits well behind the 5-HT3 and NK1 antagonists in today's guidelines.
Shares Pivotal (registrational) trial, Clinical trial, Glioma & glioblastoma.
Shares Pivotal (registrational) trial, Clinical trial, Glioma & glioblastoma.
Shares Cancer pain management, Pivotal (registrational) trial, Clinical trial.
Shares Cancer pain management, Pivotal (registrational) trial, Clinical trial.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/